Inactivated Mycobacterium obuense
Vaccineexperimental
Mycobacterium obuense is a species of soil-dwelling scotochromogenic Mycobacterium. The cell wall of M. obuense contains 1-tetradecanol, 2-octadecanol, and 2-eicosanol, and triacylated lipoproteins. — Wikipedia
Clinical trial activity
9 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01308762)
Timeline
Indications
Mechanism of action
- MycobacteriumImmunity, active
Mycobacterium immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMycobacterium obuense ↗
- NCATSIZT740JY57 ↗
Also known as
- imm-101
- mycobacterium obuense
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06498518 | Phase 2 | Jun 17, 2024 | University of Glasgow |
| NCT04442048 | Phase 3 | Jun 25, 2020 | BioCan Rx, Canadian Cancer Society, Canadian Cancer Trials Group, Canadian Centre for Applied Research in Cancer Control (ARCC), Immodulon Therapeutics Ltd, NKMAX Co., Ltd., Ontario Institute for Cancer Research, University of Ottawa |
| NCT03711188 | Phase 2 | Oct 4, 2018 | Immodulon Therapeutics Ltd, University of London |
| NCT03009058 | Phase 1/Phase 2 (Phase 2) | May 24, 2017 | Immodulon Therapeutics Ltd, Royal Marsden Hospital NHS Trust |
| NCT01559818 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Immodulon Therapeutics Ltd, University of London |
| NCT01539824 | Phase 2 | Feb 1, 2012 | Immodulon Therapeutics Ltd, Leaders In Oncology Care, Harley St, London |
| NCT01303172 | Phase 2 | Jun 1, 2011 | Immodulon Therapeutics Ltd, University of London |
| NCT01308762 | Phase 1 | Mar 1, 2010 | HCA International Limited, Immodulon Therapeutics Ltd, Theradex, University of London |
| NCT04137822 | N/A | — | Immodulon Therapeutics Ltd, myTomorrows |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immodulon Therapeutics Ltd | For profit | 8 | 6 | 4 | 2010 |
| University of London | Academic/Hospital | 4 | 0 | 2 | 2010 |
| BioCan Rx | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Canadian Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Canadian Centre for Applied Research in Cancer Control (ARCC) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| HCA International Limited | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Leaders In Oncology Care, Harley St, London | Academic/Hospital | 1 | 0 | 1 | 2012 |
| myTomorrows | Academic/Hospital | 1 | 1 | 1 | — |
| NKMAX Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
| Ontario Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Theradex | For profit | 1 | 0 | 1 | 2010 |
| University of Glasgow | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2020 |
15 organizations
Page 1 / 1